Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage
- PMID: 25081496
- DOI: 10.3171/2014.8.paradigm
Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage
Abstract
Patients receiving anticoagulation therapy who present with any type of intracranial hemorrhage--including subdural hematoma, epidural hematoma, subarachnoid hemorrhage, and intracerebral hemorrhage (ICH)--require urgent correction of their coagulopathy to prevent hemorrhage expansion, limit tissue damage, and facilitate surgical intervention as necessary. The focus of this review is acute ICH, but the principles of management for anticoagulation-associated ICH (AAICH) apply to patients with all types of intracranial hemorrhage, whether acute or chronic. A number of therapies--including fresh frozen plasma (FFP), intravenous vitamin K, activated and inactivated prothrombin complex concentrates (PCCs), and recombinant activated factor VII (rFVIIa)--have been used alone or in combination to treat AAICH to reverse anticoagulation, help achieve hemodynamic stability, limit hematoma expansion, and prepare the patient for possible surgical intervention. However, there is a paucity of high-quality data to direct such therapy. The use of 3-factor PCC (activated and inactivated) and rFVIIa to treat AAICH constitutes off-label use of these therapies in the United States. However, in April 2013, the US Food and Drug Administration (FDA) approved Kcentra (a 4-factor PCC) for the urgent reversal of vitamin K antagonist (VKA) anticoagulation in adults with acute major bleeding. Plasma is the only other product approved for this use in the United States. (1) Inconsistent recommendations, significant barriers (e.g., clinician-, therapy-, or logistics-based barriers), and a lack of approved treatment pathways in some institutions can be potential impediments to timely and evidence-based management of AAICH with available therapies. Patient assessment, therapy selection, whether to use a reversal or factor repletion agent alone or in combination with other agents, determination of site-of-care management, eligibility for neurosurgery, and potential hematoma evacuation are the responsibilities of the neurosurgeon, but ultimate success requires a multidisciplinary approach with consultation from the emergency department (ED) physician, pharmacist, hematologist, intensivist, neurologist, and, in some cases, the trauma surgeon.
Keywords: 3PCC = three-factor prothrombin complex concentrate; 4PCC = four-factor prothrombin complex concentrate; AAICH = anticoagulation-associated intracerebral hemorrhage; AF = atrial fibrillation; AHA = American Heart Association; ASA = American Stroke Association; BP = blood pressure; BT = bleeding time; CI = confidence index; CT = computed tomography; CYP = cytochrome P450; DVT = deep vein thrombosis; ECT = ecarin clotting time; ED = emergency department; FFP = fresh frozen plasma; GCS = Glasgow Coma Scale; HR = heart rate; ICES = intraoperative computed tomography-guided endoscopic surgery procedure; ICH = intracerebral hemorrhage; INR = international normalized ratio; IV = intravenous; IVH = intraventricular hemmorhage; MISTIE = Minimally Invasive Surgery plus recombinant Tissue plasminogen activator for ICH Evaluation procedure; NOAC = novel oral anticoagulant; OAC = oral anticoagulant; PCC = prothrombin complex concentrate; PE = pulmonary embolism; PHE = perihematomal edema; PT = prothrombin time; PTT = partial thromboplastin time; RR = respiratory rate; TT = thrombin time; VKA = vitamin K antigen; aPTT = activated partial thromboblastin time; bpm = beats per minute; rFVIIa = recombinant factor VII; rt-PA = recombinant tissue plasminogen activator.
Similar articles
-
Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates.Stroke. 2006 Jun;37(6):1465-70. doi: 10.1161/01.STR.0000221786.81354.d6. Epub 2006 May 4. Stroke. 2006. PMID: 16675739
-
Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding.Clin Neurol Neurosurg. 2013 Jun;115(6):770-4. doi: 10.1016/j.clineuro.2012.07.006. Epub 2012 Jul 24. Clin Neurol Neurosurg. 2013. PMID: 22835715
-
Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion.Mayo Clin Proc. 2007 Jan;82(1):82-92. doi: 10.4065/82.1.82. Mayo Clin Proc. 2007. PMID: 17285789 Review.
-
Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate.Thromb Haemost. 2014 Feb;111(2):233-9. doi: 10.1160/TH13-07-0536. Epub 2013 Oct 24. Thromb Haemost. 2014. PMID: 24154891
-
Treatment of intracerebral hemorrhage associated with new oral anticoagulant use: the neurologist's view.Clin Lab Med. 2014 Sep;34(3):587-94. doi: 10.1016/j.cll.2014.06.007. Epub 2014 Jul 29. Clin Lab Med. 2014. PMID: 25168944 Review.
Cited by
-
A retrospective comparison of the emergent use of fixed-dose four-factor prothrombin complex versus weight-based dosing for intracranial hemorrhage assessing medication delivery time and cost.Int J Physiol Pathophysiol Pharmacol. 2023 Jun 15;15(3):98-104. eCollection 2023. Int J Physiol Pathophysiol Pharmacol. 2023. PMID: 37457648 Free PMC article.
-
A retrospective cohort study of 27,049 polytraumatized patients age 60 and above: identifying changes over 16 years.Eur Geriatr Med. 2022 Feb;13(1):233-241. doi: 10.1007/s41999-021-00546-9. Epub 2021 Jul 29. Eur Geriatr Med. 2022. PMID: 34324144 Free PMC article.
-
Surgery for Coagulopathy-Related Intracerebral Hemorrhage: Craniotomy vs. Minimally Invasive Neurosurgery.Life (Basel). 2021 Jun 15;11(6):564. doi: 10.3390/life11060564. Life (Basel). 2021. PMID: 34203953 Free PMC article.
-
How do you manage ANTICOagulant therapy in neurosurgery? The ANTICO survey of the Italian Society of Neurosurgery (SINCH).BMC Neurol. 2021 Mar 3;21(1):98. doi: 10.1186/s12883-021-02126-7. BMC Neurol. 2021. PMID: 33658003 Free PMC article.
-
Coagulopathy reversal in intracerebral haemorrhage.Stroke Vasc Neurol. 2020 Feb 20;5(1):29-33. doi: 10.1136/svn-2019-000274. eCollection 2020. Stroke Vasc Neurol. 2020. PMID: 32411405 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous